Chengda Pharmaceuticals Hits Day High with 5.94% Surge Amid Market Decline

Chengda Pharmaceuticals Co., Ltd. has experienced a notable increase of 5.94% on February 24, 2026, reaching an intraday high of CNY 43.85. This performance stands in contrast to the broader market, as the China Shanghai Composite index declined by 1.26% on the same day. Over the past week, Chengda Pharmaceuticals has shown a robust gain of 14.3%, significantly outperforming the index, which only rose by 0.41%. Despite the recent uptick, the company has faced challenges in its long-term growth trajectory, with net sales declining at an annual rate of 7.38% over the last five years. The company reported a net profit of CNY -67.01 million for the first half of the year, reflecting a substantial decrease of 238.32%. Additionally, the return on capital employed stands at a low 7.29%, indicating limited profitability per unit of capital. Chengda Pharmaceuticals operates within the pharmaceuticals and biotechnology sector, with a market capitalization of CNY 3,475 million. The stock's performance over the past year has been notable, generating a return of 123.83%, compared to the China Shanghai Composite's 22.49%.